Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 7100207

Platelet crossmatch testing for donor selection.

S J Slichter
View original source ↗Export metadata ↓

Abstract

Recent studies have shown that on an average the platelets of 20-30% of HLA fully compatible donors provide poor post-transfusion platelet responses in alloimmunized refractory thrombocytopenic patients. Conversely, some HLA incompatible transfusions can provide satisfactory platelet increments for the refractory recipient. To improve the process of selecting compatible platelet donors, both lymphocytotoxic and platelet crossmatch tests have been used. Lymphocytotoxicity crossmatch tests can predict the transfusion response only 65% of the time with a high percentage of false-negative results. In contrast, several different laboratories are now reporting 84-93% predictability for platelet crossmatch tests. Because of the time and effort involved in obtaining platelets from apheresis donors and the risk of bleeding in patients not provided with compatible platelets, it seems inevitable that platelet crossmatch tests will assume an increasingly important role in the donor selection process.

Explore related subjects

Blood DonorsBlood Grouping and CrossmatchingBlood PlateletsBlood TransfusionFalse Negative ReactionsHLA AntigensHistocompatibility TestingHumansPlatelet TransfusionRiskJournal ArticleResearch Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S J Slichter. 1982. Platelet crossmatch testing for donor selection.. https://pubmed.ncbi.nlm.nih.gov/7100207/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

The prevalence of chromosomally integrated human herpesvirus 6 genomes in the blood of UK blood donors.

A lesser-recognized form of human herpesvirus 6 (HHV-6) persistence is integration of the viral genome in a host chromosome and high viral copy numbers in blood or sera are characteristic of this phenomenon. A cross-sectional study was performed to determine the frequency of high HHV-6 viral loads in whole blood (>6 log(10) copies/ml) in a population of blood donors in London, UK. Blood samples from 500 anonymized blood donors were collected from one donation center, DNA extracted, and quantitative realtime PCR used to measure viral load. Four samples (0.8%) were found to have high viral copy numbers of HHV-6 (median 6.7 log(10) copies/ml; range 6.5- 6.9 log(10) copies/ml). Cellular DNA was also quantitated using qRT-PCR for beta-globin. By comparing these two results, we calculated that there were between two and five copies of HHV-6 present per cell in these four donors. The median viral load detected in plasma from the four individuals was 3.8 log(10) copies/ml (range 3.5-4.0 log(10) copies/ml). All samples were HHV-6 variant B. In addition, a retrospective analysis of all diagnostic blood samples performed for HHV-6 in our center showed a prevalence of 2.9% of high viral loads characteristic of integration. In conclusion, high viral copy numbers of HHV-6, representing a population of viral integration, is detected in 0.8% of UK blood donors. The presence of high HHV-6 viral loads in healthy normal individuals reiterates the need to consider the confounding effect of HHV-6 viral integration in any laboratory diagnosis of HHV-6 infection.

Blood Donors↗
PubMed2007

Transfusion-associated microchimerism: a new complication of blood transfusions in severely injured patients.

Microchimerism, the stable persistence of an allogeneic cell population, can result from allogeneic exposures including blood transfusion. Transfusion-associated microchimerism (TA-MC) appears to be a common but newly recognized complication of blood transfusion. Thus far TA-MC has been detected when severely injured patients are transfused. Injury induces an immunosuppressive and inflammatory milieu in which fresh blood products with replication-competent leukocytes can sometimes cause TA-MC. TA-MC is present in approximately half of transfused severely injured patients at hospital discharge and is not affected by leukoreduction. In approximately 10% of patients, the chimerism from a single blood donor may increase in magnitude over months to years, reaching as much as 2% to 5% of all circulating leukocytes. In this review, we discuss recent studies of TA-MC in the civilian trauma population and the potential for study of TA-MC in the military population, where the severity of injury and freshness of blood products suggest that TA-MC may be even more prominent. We also discuss the need for future studies to address the immunology of TA-MC, its stem cell biology, and its clinical manifestations that have the potential to be either pathologic (autoimmunity, graft-versus-host disease) or therapeutic (tolerance induction, various cell and gene therapies).

Blood Donors↗